| Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. | |
| | |
MedLine Citation:
|
PMID: 12965939 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. OBJECTIVE: To describe the efficacy and safety of tenofovir disoproxil fumarate (tenofovir DF) compared with placebo in patients with detectable viral replication despite current antiretroviral therapy. DESIGN: Randomized, double-blind, placebo-controlled study through 24 weeks. After 24 weeks, all patients received open-label tenofovir DF for the remainder of the 48-week study. SETTING: 75 North American, European, and Australian HIV clinics. PATIENTS: 552 HIV-1-infected adults who were receiving antiretroviral therapy and had stable HIV-1 RNA levels ranging from 400 to 10,000 copies/mL. MEASUREMENTS: Change in HIV-1 RNA level (time-weighted average from baseline through week 24); proportion of patients with grade 3 or 4 laboratory abnormalities and adverse events; and genotypic HIV-1 resistance testing in a separate substudy at baseline, week 24, and week 48. RESULTS: A statistically significant decrease in HIV-1 RNA level through week 24 (the primary end point) was observed in the tenofovir DF group versus the placebo group (-0.61 log10 copies/mL vs. -0.03 log10 copies/mL, respectively [P < 0.001]; difference, -0.58 log10 copies/mL [95% CI, -0.68 to -0.49 log10 copies/mL]). In a virologic substudy, 94% of 253 patients had plasma isolates expressing reverse transcriptase mutations associated with nucleoside resistance mutations at baseline. Through week 24, the incidence of clinical adverse events was similar between patients receiving placebo and those receiving tenofovir DF (14% vs. 13%). No evidence of tenofovir DF-related toxicity was seen through week 48. CONCLUSION: In treatment-experienced patients with suboptimal viral suppression, tenofovir DF significantly reduced HIV-1 RNA level and had a safety profile similar to that of placebo. |
| | |
Authors:
|
Kathleen Squires; Anton L Pozniak; Gerald Pierone; Corklin R Steinhart; Daniel Berger; Nicholaos C Bellos; Stephen L Becker; Michael Wulfsohn; Michael D Miller; John J Toole; Dion F Coakley; Andrew Cheng; |
Related Documents
:
|
16422999 - Treating chronic hepatitis c with pegylated interferon alfa-2a (40 kd) and ribavirin in... 9256569 - Natural classes of treatment response. 8154489 - Hepatitis b virus infection in chronic uremia: long-term follow-up of a two-step integr... 15075539 - Benefit of treatment interruption in hiv-infected patients with multiple therapeutic fa... 18537189 - Entecavir therapy for lamivudine-refractory chronic hepatitis b: improved virologic, bi... 12201869 - Combination therapy for children with chronic hepatitis b virus infection. 15217169 - Long term results of anterior colporrhaphy with kelly plication for the treatment of st... 10575079 - Analysis of gait in cervical myelopathy. 20964369 - Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Annals of internal medicine Volume: 139 ISSN: 1539-3704 ISO Abbreviation: Ann. Intern. Med. Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-09-10 Completed Date: 2003-09-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: United States |
Other Details:
|
Languages: eng Pagination: 313-20 Citation Subset: AIM; IM |
Affiliation:
|
Keck School of Medicine, University of Southern California, Los Angeles, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenine
/
adverse effects,
analogs & derivatives*,
therapeutic use* Adult Anti-HIV Agents / adverse effects, therapeutic use* CD4 Lymphocyte Count Double-Blind Method Drug Resistance, Viral Female HIV Infections / drug therapy*, virology HIV-1 / drug effects*, genetics Humans Male Mutation Organophosphorus Compounds / adverse effects, therapeutic use* Phosphonic Acids* Placebos RNA / blood Viral Load |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/Organophosphorus Compounds; 0/Phosphonic Acids; 0/Placebos; 0/tenofovir disoproxil; 63231-63-0/RNA; 73-24-5/Adenine |
| Comments/Corrections | |
Summary for patients in:
|
Ann Intern Med. 2003 Sep 2;139(5 Pt 1):I22
[PMID:
12965954
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential recognition of Plasmodium falciparum merozoite surface protein 2 variants by antibodies...
Next Document: Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing an...